5 Things to Know Before The Stock Market Opens
Savings Corner
DECEMBER 23, 2023
The deal, which is expected to close in the first half of 2024, could help Bristol Myers expand its psychiatric and neurological drugs portfolio, with Karuna notably working on an experimental schizophrenia treatment currently being reviewed by the Food and Drug Administration. Bristol Myers said it will pay $330 per share for Karuna, a 53.4%
52 
Let's personalize your content